National Asset Management Inc. trimmed its position in Sanofi (NYSE:SNY) by 0.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 25,021 shares of the company’s stock after selling 140 shares during the quarter. National Asset Management Inc.’s holdings in Sanofi were worth $1,200,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Harbour Capital Advisors LLC bought a new position in Sanofi in the first quarter valued at approximately $113,000. Parallel Advisors LLC increased its stake in Sanofi by 42.5% in the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after acquiring an additional 875 shares during the last quarter. YorkBridge Wealth Partners LLC increased its stake in Sanofi by 33.7% in the second quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock valued at $147,000 after acquiring an additional 776 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its stake in Sanofi by 142.8% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock valued at $171,000 after acquiring an additional 2,098 shares during the last quarter. Finally, Proficio Capital Partners LLC increased its stake in Sanofi by 95.8% in the first quarter. Proficio Capital Partners LLC now owns 4,265 shares of the company’s stock valued at $210,000 after acquiring an additional 2,087 shares during the last quarter. 9.33% of the stock is currently owned by institutional investors and hedge funds.

In related news, major shareholder Sanofi purchased 60,595 shares of the firm’s stock in a transaction dated Wednesday, August 23rd. The shares were purchased at an average price of $478.98 per share, with a total value of $29,023,793.10. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 1.00% of the stock is owned by corporate insiders.

A number of brokerages recently issued reports on SNY. Cowen and Company reissued a “market perform” rating and issued a $52.00 price objective (up from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. BidaskClub raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. Argus reissued a “buy” rating and issued a $55.00 price objective on shares of Sanofi in a research note on Friday, September 1st. Zacks Investment Research cut shares of Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. Finally, J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi in a research note on Friday, September 15th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company’s stock. Sanofi currently has a consensus rating of “Hold” and an average target price of $53.50.

Sanofi (NYSE SNY) traded up 0.030% during mid-day trading on Thursday, hitting $49.745. 967,706 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $49.33 and its 200-day moving average price is $48.10. Sanofi has a 12 month low of $36.81 and a 12 month high of $50.65. The stock has a market cap of $124.93 billion, a PE ratio of 11.550 and a beta of 0.87.

Sanofi (NYSE:SNY) last issued its quarterly earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.74. The firm had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The company’s revenue was down 2.3% compared to the same quarter last year. Equities analysts expect that Sanofi will post $3.32 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.watchlistnews.com/sanofi-sny-position-cut-by-national-asset-management-inc/1626359.html.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.